Annual Accounts Receivable
$10.70 M
-$1.92 M-15.22%
31 December 2023
Summary:
Trinity Biotech annual accounts receivable is currently $10.70 million, with the most recent change of -$1.92 million (-15.22%) on 31 December 2023. During the last 3 years, it has fallen by -$9.33 million (-46.58%). TRIB annual accounts receivable is now -62.28% below its all-time high of $28.36 million, reached on 31 December 2006.TRIB Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$21.21 M
+$3.74 M+21.40%
30 September 2024
Summary:
Trinity Biotech quarterly accounts receivable is currently $21.21 million, with the most recent change of +$3.74 million (+21.40%) on 30 September 2024. Over the past year, it has increased by +$6.11 million (+40.50%). TRIB quarterly accounts receivable is now -40.61% below its all-time high of $35.71 million, reached on 30 June 2006.TRIB Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TRIB Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -15.2% | +40.5% |
| 3 y3 years | -46.6% | +26.1% |
| 5 y5 years | -49.8% | -14.5% |
TRIB Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -46.6% | at low | at high | +98.3% |
| 5 y | 5 years | -49.8% | at low | -14.5% | +98.3% |
| alltime | all time | -62.3% | +103.9% | -40.6% | +304.2% |
Trinity Biotech Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $21.21 M(+21.4%) |
| June 2024 | - | $17.47 M(+0.9%) |
| Mar 2024 | - | $17.32 M(+61.9%) |
| Dec 2023 | $10.70 M(-15.2%) | $10.70 M(-29.1%) |
| Sept 2023 | - | $15.10 M(+8.9%) |
| June 2023 | - | $13.87 M(+2.0%) |
| Mar 2023 | - | $13.59 M(+7.7%) |
| Dec 2022 | $12.62 M(-5.0%) | $12.62 M(-26.9%) |
| Sept 2022 | - | $17.27 M(+8.5%) |
| June 2022 | - | $15.91 M(-5.8%) |
| Mar 2022 | - | $16.90 M(+27.1%) |
| Dec 2021 | $13.29 M(-33.6%) | $13.29 M(-21.0%) |
| Sept 2021 | - | $16.82 M(+9.5%) |
| June 2021 | - | $15.36 M(+3.3%) |
| Mar 2021 | - | $14.86 M(-25.8%) |
| Dec 2020 | $20.02 M(+12.8%) | $20.02 M(-7.5%) |
| Sept 2020 | - | $21.66 M(+27.0%) |
| June 2020 | - | $17.05 M(-14.7%) |
| Mar 2020 | - | $19.98 M(+12.5%) |
| Dec 2019 | $17.75 M(-16.7%) | $17.75 M(-28.4%) |
| Sept 2019 | - | $24.81 M(+2.0%) |
| June 2019 | - | $24.33 M(+3.2%) |
| Mar 2019 | - | $23.57 M(+10.6%) |
| Dec 2018 | $21.32 M(+23.6%) | $21.32 M(-8.8%) |
| Sept 2018 | - | $23.38 M(+1.0%) |
| June 2018 | - | $23.14 M(+4.6%) |
| Mar 2018 | - | $22.12 M(+28.3%) |
| Dec 2017 | $17.24 M(-6.0%) | $17.24 M(-29.9%) |
| Sept 2017 | - | $24.60 M(-1.0%) |
| June 2017 | - | $24.86 M(+9.6%) |
| Mar 2017 | - | $22.68 M(+23.7%) |
| Dec 2016 | $18.34 M(-5.9%) | $18.34 M(-28.9%) |
| Sept 2016 | - | $25.80 M(-7.3%) |
| June 2016 | - | $27.83 M(+6.0%) |
| Mar 2016 | - | $26.26 M(+34.7%) |
| Dec 2015 | $19.50 M(-3.8%) | $19.50 M(-28.2%) |
| Sept 2015 | - | $27.15 M(-4.2%) |
| June 2015 | - | $28.34 M(+2.5%) |
| Mar 2015 | - | $27.64 M(+36.3%) |
| Dec 2014 | $20.28 M(+2.6%) | $20.28 M(-19.5%) |
| Sept 2014 | - | $25.19 M(-7.3%) |
| June 2014 | - | $27.16 M(+12.6%) |
| Mar 2014 | - | $24.13 M(+22.1%) |
| Dec 2013 | $19.76 M(+56.7%) | $19.76 M(-14.5%) |
| Sept 2013 | - | $23.12 M(+32.7%) |
| June 2013 | - | $17.43 M(+13.9%) |
| Mar 2013 | - | $15.30 M(+21.3%) |
| Dec 2012 | $12.62 M | $12.62 M(-19.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $15.57 M(+4.3%) |
| June 2012 | - | $14.92 M(-41.9%) |
| Mar 2012 | - | $25.68 M(+140.0%) |
| Dec 2011 | $10.70 M(-9.0%) | $10.70 M(-53.8%) |
| Sept 2011 | - | $23.17 M(-2.2%) |
| June 2011 | - | $23.69 M(-1.6%) |
| Mar 2011 | - | $24.08 M(+104.7%) |
| Dec 2010 | $11.76 M(-48.7%) | $11.76 M(-57.0%) |
| Sept 2010 | - | $27.37 M(-4.3%) |
| June 2010 | - | $28.59 M(+40.1%) |
| Mar 2010 | - | $20.41 M(-11.0%) |
| Dec 2009 | $22.93 M(-16.4%) | $22.93 M(-12.5%) |
| Sept 2009 | - | $26.19 M(-4.4%) |
| June 2009 | - | $27.39 M(+5.5%) |
| Mar 2009 | - | $25.95 M(-5.4%) |
| Dec 2008 | $27.42 M(+6.8%) | $27.42 M(-8.3%) |
| Sept 2008 | - | $29.91 M(+3.7%) |
| June 2008 | - | $28.83 M(+0.6%) |
| Mar 2008 | - | $28.66 M(+11.6%) |
| Dec 2007 | $25.68 M(-9.4%) | $25.68 M(-19.7%) |
| June 2007 | - | $31.97 M(-3.8%) |
| Mar 2007 | - | $33.23 M(+17.2%) |
| Dec 2006 | $28.36 M(+61.2%) | $28.36 M(-18.8%) |
| Sept 2006 | - | $34.94 M(-2.2%) |
| June 2006 | - | $35.71 M(+65.6%) |
| Mar 2006 | - | $21.56 M(+22.6%) |
| Dec 2005 | $17.59 M(+61.7%) | $17.59 M(-10.3%) |
| Sept 2005 | - | $19.61 M(+10.4%) |
| June 2005 | - | $17.76 M(+16.3%) |
| Mar 2005 | - | $15.26 M(+40.3%) |
| Dec 2004 | $10.88 M(-6.2%) | $10.88 M(-57.0%) |
| Sept 2004 | - | $25.32 M(+35.4%) |
| June 2004 | - | $18.69 M(+25.4%) |
| Mar 2004 | - | $14.91 M(+28.5%) |
| Dec 2003 | $11.60 M(+18.4%) | $11.60 M(-20.5%) |
| Sept 2003 | - | $14.59 M(-6.5%) |
| June 2003 | - | $15.61 M(+10.8%) |
| Mar 2003 | - | $14.09 M(+43.8%) |
| Dec 2002 | $9.80 M(+86.8%) | $9.80 M(-8.4%) |
| Sept 2002 | - | $10.70 M(+12.9%) |
| June 2002 | - | $9.48 M(+12.9%) |
| Mar 2002 | - | $8.40 M(+60.0%) |
| Dec 2001 | $5.25 M(-34.2%) | $5.25 M(-41.0%) |
| Sept 2001 | - | $8.89 M(+6.8%) |
| June 2001 | - | $8.32 M(+1.1%) |
| Mar 2001 | - | $8.24 M(+3.3%) |
| Dec 2000 | $7.97 M(+10.5%) | $7.97 M(+10.5%) |
| Dec 1999 | $7.21 M(+7.6%) | $7.21 M(+7.6%) |
| Dec 1998 | $6.70 M | $6.70 M |
FAQ
- What is Trinity Biotech annual accounts receivable?
- What is the all time high annual accounts receivable for Trinity Biotech?
- What is Trinity Biotech annual accounts receivable year-on-year change?
- What is Trinity Biotech quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Trinity Biotech?
- What is Trinity Biotech quarterly accounts receivable year-on-year change?
What is Trinity Biotech annual accounts receivable?
The current annual accounts receivable of TRIB is $10.70 M
What is the all time high annual accounts receivable for Trinity Biotech?
Trinity Biotech all-time high annual accounts receivable is $28.36 M
What is Trinity Biotech annual accounts receivable year-on-year change?
Over the past year, TRIB annual accounts receivable has changed by -$1.92 M (-15.22%)
What is Trinity Biotech quarterly accounts receivable?
The current quarterly accounts receivable of TRIB is $21.21 M
What is the all time high quarterly accounts receivable for Trinity Biotech?
Trinity Biotech all-time high quarterly accounts receivable is $35.71 M
What is Trinity Biotech quarterly accounts receivable year-on-year change?
Over the past year, TRIB quarterly accounts receivable has changed by +$6.11 M (+40.50%)